Search
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalZanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[ … In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada.
Pegzilarginase
go.drugbank.com/drugs/DB14780ApprovedFDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).
Synonyms: Optimised human arginase I, Co-ArgI-PEG modified human arginase IImiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.
Fluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigationalFluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.
Methacholine
go.drugbank.com/drugs/DB06709ApprovedAsthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing … [L31763] In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR.
Aluminum sesquichlorohydrate
go.drugbank.com/drugs/DB11108ApprovedAluminum sesquichlorohydrate is an aluminum salt used as an antiperspirant agent, cosmetic astringent and deodorant agent. It works by physically blocking eccrine sweat gland ducts [A31171].
Mixtures: Lactovit DEODORANT ROLL-ON MEN INVISIBLE, Lactovit Mens Roll On Antiperspirant DeodorantProducts: AINNARA Roll-On, CARDIGAN Roll-OnDuloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Synonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amineRaxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigationalIt works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575] … Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.